Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 4, 2010, Pages 502-508

  Giannini, E G ^a   Basso, M ^a   Savarino, V ^a   Picciotto, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL EVALUATION; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTIVIRAL AGENTS; BODY MASS INDEX; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 74049109303     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04201.x     Document Type: Article

References (20)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007 13 : 2436 2441.
2. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001 33 : 455 463.
3. Hoofnagle HJ. Course and outcome of hepatitis. Hepatology 2002 36 : S21 9.
4. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
6. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002 36 : S114 20.
7. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006 43 (2 Suppl 1 S207 20.
8. Ciancio A, Smedile A, Giordanino C, et al. Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured? Am J Gastroenterol 2006 101 : 1811 1816.
9. Formann E, Steindl-Munda P, Hofer H, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006 23 : 507 511.
10. Desmond CP, Roberts SK, Dudley F, et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006 13 : 311 315.
11. George SI, Bacon BR, Brunt EM, Mihindukulasuriya KI, Hoffman J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009 49 : 729 738.
12. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 699.
13. Swain M, Lai MY, Shiffman ML, et al. Durability of sustained virological response (SVR) after treatment with peginterferon alfa-2a (40KD) (Pegasys) alone or in combination with ribavirin (Copegus): results of an ongoing long-term follow-up study. Hepatology 2004 40 (Suppl. 1 400A 1A.
14. Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007 13 : 2467 2478.
15. Landau DA, Saadoun D, Calabrese LH, Cacoub P. The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev 2007 6 : 581 587.
16. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004 78 : 5867 5874.
17. Radkowski M, Gallegos-Orozco JF, Jablonsak J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005 41 : 106 114.
18. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002 51 : 89 94.
19. Bressler BM, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003 38 : 639 644.
20. Diaz O, Delers F, Maynard M, et al. Preferential association of hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol 2006 87 : 2983 2991.